Abstracts tagged "registry"

Abstract Number: 0354 • ACR Convergence 2021
A Cross-Sectional Study of Rheumatoid Arthritis Diagnoses in Patients with Systemic Lupus Erythematosus
Kathryn Starzyk¹, Gary Curhan² and Julia Brault², ¹OM1, Inc, Boston, MA, ²OM1, Boston, MA
Background/Purpose: Features of autoimmune conditions may coexist in individual patients, which may represent an overlapping single disease with features of both (i.e., ‘rhupus’), or the…
Abstract Number: 1364 • ACR Convergence 2021
Autologous Hematopoietic Stem Cell (HSC) Transplantation for Systemic Sclerosis, North American Registry: Updated Outcomes and the Impact of CD34+ HSC Enrichment
George Georges¹, Keith Sullivan², Dinesh Khanna³, Matthew Mei⁴, Maureen Mayes⁵, Dan Furst⁶, Mark Wener⁷, Suzanne Kafaja⁸, Gwynn Long², Vaishali Sanchorawala⁹, Kareem Jamani¹⁰, Attaphol Pawarode³, Ashish Masurekar¹¹, Brian Lam¹², Richard Nash¹³, Marcin Trojanowski⁹, Chitra Hosing¹⁴, Philip Clements¹⁵, Tanya Helms², Bernadette McLaughlin¹⁶, Linda Griffith¹⁷, Kyle Hebert¹⁸, Mary Eapen¹⁸, Jan Storek¹⁰ and Harold Atkins¹¹, ¹Fred Hutchison Cancer Research Center and University of Washington, Seattle, WA, ²Duke University School of Medicine, Durham, NC, ³University of Michigan, Ann Arbor, MI, ⁴City of Hope Comprehensive Cancer Center, Duarte, CA, ⁵Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, ⁶University of California Los Angeles, Los Angeles, CA, ⁷University of Washington, Seattle, WA, ⁸University of California Los Angeles Division of Rheumatology, Los Angeles, CA, ⁹Boston University School of Medicine, Boston, MA, ¹⁰University of Calgary, Calgary, AB, Canada, ¹¹Ottawa Hospital Research Institute, Ottawa, ON, Canada, ¹²University of Texas McGovern Medical School, Houston, TX, ¹³Colorado Blood Cancer Institute, Denver, CO, ¹⁴University of Texas MD Anderson Cancer Center, Houston, TX, ¹⁵University of California Los Angeles School of Medicine, Department of Rhemumatology, Los Angeles, CA, ¹⁶Fred Hutchison Cancer Research Center, Seattle, WA, ¹⁷Division of Allergy Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, ¹⁸Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Autologous hematopoietic stem cell transplantation (AHSCT) is now established as a preferred standard of care treatment for patients with severe scleroderma with internal organ…
Abstract Number: 0372 • ACR Convergence 2021
Impact of Gender and Age on Ankylosing Spondylitis Patient Profiles at Golimumab Initiation and 12-Month Outcomes
Ariel Masetto¹, Proton Rahman², Michelle Teo³, Pauline Boulos⁴, Emmanouil Rampakakis⁵, Meagan Rachich⁶, Allen Lehman⁶, Francois Nantel⁷ and Odalis Asin-Milan⁶, ¹Universite de Sherbrooke, Sherbrooke, QC, Canada, ²Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ³Penticton Regional Hospital, Penticton, BC, Canada, ⁴., Hamilton, ON, Canada, ⁵JSS Medical Research, Montréal, QC, Canada, ⁶Janssen Inc., Toronto, ON, Canada, ⁷., Montréal, QC, Canada
Background/Purpose: Gender and age have been previously identified as independent predictors of response to anti-TNFs. The aim of this analysis was to compare, between genders…
Abstract Number: 1442 • ACR Convergence 2021
Effectiveness of Cycling JAKi Compared to Switching to bDMARD in Patients Who Failed a First JAKi in an International Collaboration of Registries of Rheumatoid Arthritis Patients (the JAK-pot Study)
Manuel Pombo-Suarez¹, Carlos Sanchez-Piedra², Juan J Gomez-Reino³, Kim Lauper⁴, Nevsun Inanc⁵, Anja Strangfeld⁶, Doreen Huschek⁷, Karel Pavelka⁸, Eirik Kristianslund⁹, Tore Kvien¹⁰, Ziga Rotar¹¹, Dan Nordström¹², Denis Choquette¹³, Ori Elkayam¹⁴, Burkhard Leeb¹⁵, Maria José Santos¹⁶, Kimme Hyrich¹⁷, Lianne Kearsley-Fleet¹⁸, Catalin Codreanu¹⁹, Denis Monguin²⁰, Delphine Courvoisier²⁰ and Axel Finckh²¹, ¹Rheumatology Service, Hospital Clinico Universitario, Santiago De Compostela, Santiago de Compostela, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ³Hospital Clínico Universitario, Santiago de Compostela, Spain, ⁴Geneva University Hospitals, Geneve, Switzerland, ⁵Division of Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ⁶Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁷Epidemiology and Health Services Research, German Rheumatism Research Center, Berlin, Germany, Berlin, Germany, ⁸Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁹Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ¹⁰Diakonhjemmet Hospital, Oslo, Norway, ¹¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia, ¹²Division of Internal Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland, ¹³Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ¹⁴Tel Aviv Medical Center, Tel Aviv, Israel, ¹⁵Karl Landsteiner University for Health Sciences, Krems/Donau, Karl Landsteiner Institute for Clinical Rheumatology, Hollabrunn, Austria, ¹⁶Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal, ¹⁷University of Manchester, Manchester, United Kingdom, ¹⁸Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ¹⁹Center of Rheumatic Diseases, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania, ²⁰Division of Rheumatology, Geneva University Hospital, Geneva, Switzerland, ²¹University Hospital of Geneva, Geneve - Vesenaz, Switzerland
Background/Purpose: With the arrival of new Janus kinase inhibitors (JAKi), with different JAK inhibition profiles, there is the possibility of using a second JAKi in…
Abstract Number: 0568 • ACR Convergence 2021
Construction of the Veterans Affairs National Rheumatoid Arthritis Database (VANRAD)
Amy Joseph¹, Jodi Yanagida¹, Xinliang Huang¹, Prabha Ranganathan¹, Melissa Laurie², Hong Xian¹ and Seth Eisen¹, ¹VA St. Louis Health Care System, St. Louis, MO, ²Bristol Myers Squibb, Princeton, NJ
Background/Purpose: The Department of Veterans Affairs (DVA) provides comprehensive medical care at minimal or no cost to 9 million veterans annually through 170 medical centers…
Abstract Number: 1624 • ACR Convergence 2021
Patient-Reported Care Utilization, Socioeconomic Status, and Health Status Among Young Adults with JIA
Emily Smitherman¹, Rouba Chahine¹, Nicole Bitencourt², AKM Rahman¹, Erica Lawson³ and Joyce Chang⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Loma Linda University Medical Center, Redlands, CA, ³University of California San Francisco, San Francisco, CA, ⁴Boston Children's Hospital, Brookline, MA
Background/Purpose: Young adulthood is a vulnerable period for individuals with childhood-onset rheumatic diseases, especially the transition from pediatric to adult care. Our objective was to…
Abstract Number: 0658 • ACR Convergence 2021
ACCORD: A Novel Rheumatology Transition Clinic Structure for Adolescent and Young Adult Patients with Childhood Onset Rheumatic Disease
Rebecca Overbury¹, Kelly Huynh², Tracy Frech¹, John Bohnsack¹ and Aimee Hersh¹, ¹University of Utah, Salt Lake City, UT, ²Intermountain Health Care, Salt Lake City, UT
Background/Purpose: The transition of health care from Pediatric to Adult providers for adolescents and young adults with childhood onset rheumatic disease continues to be associated…
Abstract Number: 1779 • ACR Convergence 2021
A Comparison of Quality of Life Outcomes Between Psoriatic Arthritis and Psoriasis Patients: Data from the Brigham Cohort for Psoriasis and Psoriatic Arthritis Registry (COPPAR)
Nancy Shadick¹, Kumiko Schnock², Vivi Feather², Jing Cui³, Gabriela Maica², Alexa Marshall², Wynona Francis², Muibat Yussuff², Lourdes Maria Perez Chada², Michael E. Weinblatt² and Joseph Merola⁴, ¹Brigham & Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: To report the demographics, clinical characteristics, and differential impacts on quality of life measures among participants in the Psoriasis (PsO) and Psoriatic Arthritis (PsA)…
Abstract Number: 0766 • ACR Convergence 2021
Baseline Characteristics and Patient Reported Outcomes from a Juvenile Dermatomyositis Registry Inception Cohort
Jessica Neely¹, Kaveh Ardalan², Adam Huber³ and Susan Kim⁴, ¹University of California San Francisco, San Francisco, CA, ²Duke University Medical Center, Durham, NC, ³Dalhousie University, Halifax, NS, Canada, ⁴UCSF Benioff Children's Hospital, San Francisco, CA
Background/Purpose: Juvenile dermatomyositis (JDM), the most common inflammatory myopathy of children, is rare, with an estimated incidence of 2-4 in 1 million children. Given the…
Abstract Number: 1793 • ACR Convergence 2021
Impact of Gender and Age on Psoriatic Arthritis Patient Profiles at Golimumab Initiation and 12-Month Outcomes
Arthur Karasik¹, Isabelle Fortin², Proton Rahman³, Regan Arendse⁴, Emmanouil Rampakakis⁵, Odalis Asin-Milan⁶, Allen Lehman⁶, Francois Nantel⁷ and Meagan Rachich⁶, ¹Arthur Karasik Medicine Professional Corporation, Toronto, ON, Canada, ²CREQ, Rimouski, QC, Canada, ³Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁴University of Saskatchewan, Saskatoon, SK, Canada, ⁵JSS Medical Research, Montréal, QC, Canada, ⁶Janssen Inc., Toronto, ON, Canada, ⁷., Montréal, QC, Canada
Background/Purpose: Gender and age have been previously identified as independent predictors of response to anti-TNFs. The aim of this analysis was to compare, between genders…
Abstract Number: 0794 • ACR Convergence 2021
Application of Treat to Target and Impact of Sustained Low Disease Activity or Remission on Function in Rheumatoid Arthritis Patients
Louis Bessette¹, Edward Keystone², Proton Rahman³, Keltie Anderson⁴, Emmanouil Rampakakis⁵, Allen Lehman⁶, Meagan Rachich⁶, Francois Nantel⁷ and Odalis Asin-Milan⁶, ¹Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ²Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ³Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁴University of Saskatchewan, Saskatoon, SK, Canada, ⁵JSS Medical Research, Montréal, QC, Canada, ⁶Janssen Inc., Toronto, ON, Canada, ⁷., Montréal, QC, Canada
Background/Purpose: The aim of this analysis was to compare between enrolment periods RA treatment outcomes and frequency of treating to target, and to assess the…
Abstract Number: 1794 • ACR Convergence 2021
Application of Treat to Target and Impact of Sustained Low Disease Activity or Remission on Function in Psoriatic Arthritis Patients
Proton Rahman¹, Regan Arendse², Philip Baer³, Michel Zummer⁴, Emmanouil Rampakakis⁵, Allen Lehman⁶, Meagan Rachich⁶, Francois Nantel⁷ and Odalis Asin-Milan⁶, ¹Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ²University of Saskatchewan, Saskatoon, SK, Canada, ³Baer Weinberg MPC, Scarborough, ON, Canada, ⁴CH Maisonneuve-Rosemont, Montréal, QC, Canada, ⁵JSS Medical Research, Montréal, QC, Canada, ⁶Janssen Inc., Toronto, ON, Canada, ⁷., Montréal, QC, Canada
Background/Purpose: Previous analyses have identified enrolment year as an independent predictor of real-world retention on anti-TNF treatment whereby patients enrolled in later periods were more…
Abstract Number: 0454 • ACR Convergence 2020
Anticytokine Therapies for Inflammatory Rheumatic Disease (IRD) Are Associated with Reduced Hospitalisation Following Community COVID-19 Infection; Results of the Trinity Rheumatology and Covid-19 Registry – TRACR
Rachael Flood¹, Richard Conway², David Kane¹ and Ronan Mullan¹, ¹Tallaght University Hospital, Dublin, Ireland, ²St James's Hospital, Dublin, Ireland
Background/Purpose: Anticytokine biological disease modifying anti-rheumatic drugs (bDMARD), which are widely prescribed for Inflammatory Rheumatological Diseases (IRD) are currently undergoing clinical trials for the treatment…
Abstract Number: 1029 • ACR Convergence 2020
Clinical Characteristics of Patients with Axial Spondyloarthritis in China: Results from the ChinaAS Registry
Jinmei Su¹, Runsheng Wang², Ping Zhu³, Yanhong Wang⁴, Shangzhu Zhang¹, Linyi Peng¹, Min Yang⁵, Ling Lei⁶, Li Qin⁷, Mengtao Li⁸ and Xiaofeng Zeng⁸, ¹Peking Union Medical College Hospital, Department of Rheumatology, Beijing, China (People's Republic), ²Columbia University Irving Medical Center, Division of Rheumatology, New York, NY, ³Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China (People's Republic), ⁴Department of Epidemiology and Bio-statistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, Beijing, China (People's Republic), ⁵Department of Rheumatology and Immunology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China (People's Republic), ⁶Department of Rheumatology and Immunology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China (People's Republic), ⁷Department of Rheumatology, The First People's Hospital of Yunnan Province, Kunming, China (People's Republic), ⁸Peking Union Medical College Hospital, Department of Rheumatology, Beijing, Beijing, China (People's Republic)
Background/Purpose: The ChinaAS is a nationwide, multicenter registry of patients with axial spondyloarthritis (SpA) in China to facilitate research in epidemiology, pathogenesis, diagnosis and treatment…
Abstract Number: 0601 • ACR Convergence 2020
The “Why” of Drug Discontinuation; Clinical Review of EMR Notes for 2,545 Patients with Rheumatic Diseases
Kent Kwas Huston¹, Simon Helfgott², Scott Milligan³, Jasvinder Singh⁴, Nehad Soloman⁵, Brandon Weil³ and Colin Edgerton⁶, ¹Kansas City Physician Partners, Kansas City, MO, ²BWH- HMS, Boston, MA, ³Trio Health, Louisville, CO, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, ⁶Articularis Healthcare, Summerville, SC
Background/Purpose: Persistence on therapy is an important consideration in rheumatic diseases. There are multiple treatment options that influence long term disease management and a better…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].